News

News and Press Releases
Research | CFTR Modulators FDA Approves Expansion of Modulators for People With Certain Rare Mutations

The U.S. Food and Drug Administration (FDA) today expanded its approval of three CFTR modulators to include additional people with CF who have certain rare mutations. The approval enables more than 600 individuals with CF who were not previously eligible for modulators to access drugs that treat the underlying cause of their disease for the first time.

| 3 min read
Research | About the CF Foundation | Our Research Approach Cystic Fibrosis Foundation Announces Nine Research Agreements to Advance Its Path to a Cure

The Cystic Fibrosis Foundation announced a new set of research agreements to drive progress on its Path to a Cure. The nine awards will advance a variety of tools and strategies to accelerate treatments for the underlying cause of cystic fibrosis for all people with CF, regardless of their mutations.

| 4 min read
About the CF Foundation | Our Research Approach CF Foundation Awards $2.76 Million for 11 COVID-19 Studies

Today, the Cystic Fibrosis Foundation awarded $2.76 million for 11 laboratory studies that will advance our understanding of the underlying factors that impact COVID-19 outcomes in people with cystic fibrosis. Ultimately, insights gained from this body of research may be used to improve future treatments.

| 5 min read
Research | Antibiotics | About the CF Foundation CF Foundation Awards Up to $3.3M to Polyphor for Inhaled Version of Antibiotic to Treat Pseudomonas

Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. About 17% of individuals with CF who had Pseudomonas infections last year had multi-drug resistant strains.

| 3 min read
Our Research Approach | About the CF Foundation CF Foundation Awards up to $3.75M to Matinas BioPharma to Develop Oral Version of Antibiotic for NTM Infections

Potential oral formulation of drug targeting nontuberculous mycobacteria infections could reduce side effects of current treatment 

| 3 min read
Get Involved | About the CF Foundation CF Foundation busca la participación de las comunidades afroamericana, latina, indígena, asiática, de Medio Oriente y otras personas de color

Poner atención a la diversidad de voces es fundamental a medida que continuamos con  nuestra meta de escuchar, aprender y actuar contra el racismo y la discriminación.

| 5 min read
Get Involved | About the CF Foundation CF Foundation Seeks Input from Communities of Color

Hearing from diverse voices is critical as we continue our journey to listen, learn, and take action against racism and discrimination.

| 4 min read
Coronavirus (COVID-19) Global Study Reports Updated COVID-19 Outcomes in People With Cystic Fibrosis

The Cystic Fibrosis Registry Global Harmonization Group published in the Journal of Cystic Fibrosis updated data on the impact of COVID-19 on people with CF. The manuscript reports on 181 people with cystic fibrosis from 19 countries diagnosed with COVID-19.

| 4 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Awards up to $2.4M for a New Approach to Reduce Infections

Potential treatment from Calithera Biosciences minimizes growth of germs in the lungs

| 3 min read
CFTR Modulators | About the CF Foundation A Message From Our CEO

The CF Foundation has successfully completed a sale of its remaining stake in royalties related to Vertex's CFTR modulators for an upfront payment of $575 million and a potential future payment of $75 million, bringing additional resources to the fight against CF.

| 3 min read